Article
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Oncotarget - 1 Dec 2012
Cassuto Ophélie, Dufies Maeva, Jacquel Arnaud, Robert Guillaume, Ginet Clémence, Dubois Alix, Hamouda Amine, Puissant Alexandre, Luciano Fredéric, Karsenti Jean-Michel, Legros Laurence, Cassuto Jill Patrice, Lenain Pascal, Auberger Patrick
Abstract excerpt
The advent of tyrosine kinase inhibitor (TKI) therapy has considerably improved the survival of patients suffering chronic myelogenous leukemia (CML). Indeed, inhibition of BCR-ABL by imatinib, dasatinib or nilotinib triggers durable responses in most patients suffering from this disease. Moreover, resistance to imatinib due to kinase domain mutations can be generally circumvented using dasatinib or nilotinib,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.